Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Increased Gene Therapy Efficacy Through the Use of Extended Half-Life Clotting Factors.

Blood advances·2026

Same author

Matchmaking gene therapy with mimetic antibodies.

Blood·2025

Same author

CRISPR and gene editing technologies for bleeding disorders.

Therapeutic advances in hematology·2025

Same author

Long-Term Functional Correction of Pompe Disease and Increased α-Glucosidase Expression after Gene Therapy with Novel Combinations of Muscle-Targeted Transcriptional <i>Cis</i>-Regulatory Elements.

Human gene therapy·2025

Same author

Comprehensive analysis of off-target and on-target effects resulting from liver-directed CRISPR-Cas9-mediated gene targeting with AAV vectors.

Molecular therapy. Methods & clinical development·2024

Same author

Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy.

Molecular metabolism·2024

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Recent advances in lentiviral vector development and applications.

Janka Mátrai¹, Marinee K L Chuah, Thierry VandenDriessche

¹Flanders Institute for Biotechnology, VIB, Vesalius Research Center, University of Leuven, Leuven, Belgium.

Molecular Therapy : the Journal of the American Society of Gene Therapy

|January 21, 2010

Summary

Lentiviral vectors (LVs) offer safe and effective gene transfer for treating diseases. Advances in LV technology improve safety and efficacy, paving the way for clinical applications.

More Related Videos

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Related Experiment Videos

Last Updated: Jun 16, 2026

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Area of Science:

Molecular Biology
Gene Therapy
Virology

Background:

Lentiviral vectors (LVs) are advanced tools for gene transfer into various cell types.
They show promise for treating genetic diseases, with successful applications in animal models.

Purpose of the Study:

To review the advancements in lentiviral vector technology.
To highlight their potential in gene therapy and clinical applications.

Main Methods:

Review of current literature on lentiviral vector applications.
Analysis of vector design modifications for improved safety and efficacy.
Discussion of strategies to mitigate risks like insertional mutagenesis.

Main Results:

LVs efficiently transduce both dividing and non-dividing cells, including stem cells.
Modified LVs demonstrate targeted gene delivery and reduced immunogenicity.
Integration profiles of LVs are more favorable than gamma-retroviral vectors, with strategies to minimize risks.

Conclusions:

Lentiviral vectors are versatile and increasingly safe tools for gene therapy.
Recent innovations enhance LV efficacy and safety, supporting their clinical translation.